Annual report
3034.TEDINET S100TXD7
Period2023-04-01 → 2024-03-31
Filed2024-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥180.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥170.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥166.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥161.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥165.4bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥8.3bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥9.5bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥9.3bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥10.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥10.1bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.4bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.0bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥8.9bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥9.6bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.5bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.4bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.1bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥4.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥5.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥117.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥101.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥96.0bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥100.6bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥102.9bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥64.9bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥53.0bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥52.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥48.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥43.9bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥41.8bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥41.0bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥27.3bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥18.8bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥26.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥19.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥15.8bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥13.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥11.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥10.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥12.9bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥13.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥8.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥8.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥10.0bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥225m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥131.11 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥152.96 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥149.51 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥89.55 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥107.23 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,414.43 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,314.69 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,189.7 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,124.31 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,074.57 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 44.8% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.7% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.9% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.4% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 9.6% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.2% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.9% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 5,856 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 5,746 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 5,620 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 5,517 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 5,366 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥8.7bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥8.3bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥7.0bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥7.1bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥4.2bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥6.8bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥6.5bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥7.0bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥6.6bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥5.5bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.5bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.1bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥6.8bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥6.6bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥6.7bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥6.6bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥5.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥5.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥3.1bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥93.6bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥77.5bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥67.4bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥63.9bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥57.8bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥41.1bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥30.8bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥52.5bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥46.7bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥40.8bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥36.2bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥33.3bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥13.2bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥5.5bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥179.61 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥178 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥146.91 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥147.45 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥80.76 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥30 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥32 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,407.23 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,258.81 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,108.12 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥987.71 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥884.2 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 56.1% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.3% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.6% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.6% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.6% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 13.5% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.0% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.9% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 38,902,785 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 66 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 66 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 56 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 49 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 50 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥98m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥55m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥478m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥478m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥14.0bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥3.5bn |
| Health Insurance Pharmacyreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥4.0bn |
| Health Insurance Pharmacyreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥1.5bn |
| Health Insurance Pharmacyreportable segment | employees | at 2024-03-31 | 4921 pure |
| Health Insurance Pharmacyreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥165.2bn |
| Health Insurance Pharmacyreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥165.1bn |
| Health Insurance Pharmacyreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥89m |
| Health Insurance Pharmacyreportable segment | segment assets | at 2024-03-31 | ¥92.4bn |
| Health Insurance Pharmacyreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥10.7bn |
| Medical Related Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥939m |
| Medical Related Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥151m |
| Medical Related Businessreportable segment | employees | at 2024-03-31 | 819 pure |
| Medical Related Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥15.3bn |
| Medical Related Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥15.0bn |
| Medical Related Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥389m |
| Medical Related Businessreportable segment | segment assets | at 2024-03-31 | ¥11.4bn |
| Medical Related Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥180.5bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥180.1bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥478m |
| —segment total | segment assets | at 2024-03-31 | ¥103.8bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥11.9bn |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥170m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥29m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥404m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥404m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | −¥1.2bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥3.5bn |
| Health Insurance Pharmacyreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥8.5bn |
| Health Insurance Pharmacyreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥1.4bn |
| Health Insurance Pharmacyreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥155.4bn |
| Health Insurance Pharmacyreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥155.4bn |
| Health Insurance Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥76m |
| Health Insurance Pharmacyreportable segment | segment assets | at 2023-03-31 | ¥92.1bn |
| Health Insurance Pharmacyreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥11.5bn |
| Medical Related Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥205m |
| Medical Related Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥118m |
| Medical Related Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥15.0bn |
| Medical Related Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥14.7bn |
| Medical Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥328m |
| Medical Related Businessreportable segment | segment assets | at 2023-03-31 | ¥11.0bn |
| Medical Related Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.5bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥8.7bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥1.5bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥170.4bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥170.0bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥404m |
| —segment total | segment assets | at 2023-03-31 | ¥103.1bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥13.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,469
| Item | Context | Value | Unit |
|---|---|---|---|
| Shareholding ratio | CurrentYearInstant_No6MajorShareholdersMember | 0.0347 | |
| Number of shares held | CurrentYearInstant_No7MajorShareholdersMember | 1304000 | |
| Shareholding ratio | CurrentYearInstant_No7MajorShareholdersMember | 0.0345 | |
| Number of shares held | CurrentYearInstant_No8MajorShareholdersMember | 1104000 | |
| Shareholding ratio | CurrentYearInstant_No8MajorShareholdersMember | 0.0292 | |
| Number of shares held | CurrentYearInstant_No9MajorShareholdersMember | 974400 | |
| Shareholding ratio | CurrentYearInstant_No9MajorShareholdersMember | 0.0258 | |
| Number of shares held | CurrentYearInstant_No10MajorShareholdersMember | 775700 | |
| Shareholding ratio | CurrentYearInstant_No10MajorShareholdersMember | 0.0205 | |
| Number of shares held | CurrentYearInstant | 21468966 | |
| Shareholding ratio | CurrentYearInstant | 0.5694 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 1200200 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 37669800 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 376698 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 32785 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 38902785 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 376698 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 1200200 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 1200200 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0308 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | 1200200 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | 1200200 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | 0.0308 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row1Member | 565000000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row1Member | 15 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row2Member | 565000000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row2Member | 15 | |
| Number of male directors and other officers | FilingDateInstant | 9 | |
| Number of female directors and other officers | FilingDateInstant | 2 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.181 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E03476-000NakamuraTakashiMember | 1641000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E03476-000IshiiTakayoshiMember | 14927 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E03476-000FukumitsuKiyonobuMember | 63400 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E03476-000OnchiYukariMember | 33600 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E03476-000TogashiYutakaMember | 24054 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E03476-000ImaiKeiMember | 6992 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E03476-000KubokiToshikoMember | 3000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E03476-000YamamotoYukiharuMember | 4800 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E03476-000YasutoshiMoriMember | 100 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E03476-000MiyazakiMotoyukiMember | 1700 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E03476-000KazuoIshiiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 1793573 | |
| Audit fees reporting company | Prior1YearDuration | 29000000 | JPY |
| Non audit fees reporting company | Prior1YearDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |